— Know what they know.
Not Investment Advice

OSUR NASDAQ

OraSure Technologies, Inc.
1W: +13.3% 1M: +6.1% 3M: +3.7% YTD: +75.2% 1Y: +44.8% 3Y: -22.1% 5Y: -60.5%
$4.16
-0.01 (-0.24%)
After Hours: $4.36 (+0.20, +4.81%)
Weekly Expected Move ±8.2%
$3 $4 $4 $4 $5
NASDAQ · Healthcare · Medical - Instruments & Supplies · Tech Score Strong Buy · Power 63 · $286.9M mcap · 57M float · 0.910% daily turnover · Short 43% of daily vol
Credit Risk of going bust: lower than 73% of companies Debt: 4.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.6%), OraSure Technologies, Inc. would be worth roughly what it owes.
Total debt $12.1M against a stock market value of $287.6M.
Distance to default 8.05 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $6.0M (short-term plus half of long-term), stock volatility 48.3%; Altman Z 3.78. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$286.9M
52W Range2.08-4.58
Volume869,691
Avg Volume518,078
Beta1.02
Dividend—
Analyst Ratings
4 Buy 9 Hold 0 Sell
Consensus Hold
Company Info
CEOCarrie Eglinton Manner
Employees500
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date1986-11-17
220 East First Street
Bethlehem, PA 18015
US
610 882 1820
About OraSure Technologies, Inc.

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Recent Insider Trades

NameTypeSharesPriceDate
Boyd Steven Kyle A-Award 4,797 $3.88 2026-09-29
Kenny John P. F-InKind 5,116 $3.43 2026-09-06
Boyd Steven Kyle A-Award 3,666 $4.43 2026-06-26
McMahon Robert W. A-Award 46,106 — 2026-06-03
Gagliano Nancy J A-Award 46,106 — 2026-06-03

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms